Synthesis, characterization and biological activity of novel ionic liquids with bis-imidazole moieties: antitumor, antimicrobial effects and molecular docking studies

Creative Commons License


Organic Communications, vol.17, no.1, pp.23-37, 2024 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.25135/acg.oc.163.2401.4014
  • Journal Name: Organic Communications
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier
  • Page Numbers: pp.23-37
  • Keywords: anticancer effects, antimicrobial activity, Bis imidazolium ionic liquids, molecular docking
  • Yozgat Bozok University Affiliated: Yes


In this study, bis-Schiff bases with imidazole (2) and bis-imidazolium liquids (3a-g) were synthesized. The new compounds were characterized by Fourier transform infrared (FTIR), proton and carbon-13 nuclear magnetic resonance spectroscopy (1H- and 13C- NMR). The MTT assay was performed by our research group to measure the anticancer effect of the synthesized molecules on cell proliferation (NCI-60 screening method). Accordingly, when molecules 3e, 3g and 3f were compared with other molecules and 5-Fluorouracil (5FU) (positive control), they were found to exhibit potent anticancer activity against all cancer cell lines ((Growth inhibition (GI50): 1.0 - 1.82, total growth inhibition (TGI): 1.09 - 4.79 and lethal concentration (LC50): 2.74 – 59.5 µg/mL), but also a strong cytotoxic effect on normal lung cells Beas2B and normal cartilage cells HC (GI50: 1.0 - 1.28, TGI: 1.03 - 2.61 and LC50: 1.77 - 41.7 µg/mL). The in vitro antimicrobial activity of the synthesized compounds was evaluated against a range of microorganisms, including four Gram-positive bacteria (B. cereus, S. aureus, E. faecalis, B. subtilis), four Gram-negative bacteria (Y. pseudotuberculosis, P. aeruginosa, E. coli, K. pneumoniae) and two yeast-like fungi (C. albicans, C. tropicalis). Molecular docking calculations were performed to investigate the ligand-protein interactions between the compounds and the Epidermal Growth Factor Receptor (EGFR) and the Vascular Endothelial Growth Factor Receptor (VEGFR1).